Sarepta Therapeutics
SRPT
17.50
+0.19
+1.10%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
17.50
+0.19
+1.10%
Live - 5344 symbols - heartbeat 418s ago
· 2026-10-08 08:08
Pre-market
17.50
0.00%
After-hours
17.69
+1.09%
Overnight
17.62
+0.69%
- Market cap
- 1.85B
- P/E (TTM)i
- -11.15
- P/Bi
- 1.21
- EPSi
- -7.13
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on SRPT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 16 analysts
Hold
Avg price target
22.43 +28.2%
Price target rangecurrent 17.50
Low5.00
Avg22.43
High38.00
Buy 25%
Hold 56%
Sell 19%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | H.C. Wainwright | -- | SELL | 5.00 |
| 2026-10-02 | Wells Fargo | -- | BUY | 38.00 |
| 2026-09-30 | Wedbush | -- | BUY | 35.00 |
| 2026-09-30 | J.P. Morgan | -- | HOLD | 20.00 |
| 2026-09-28 | William Blair | -- | HOLD | -- |
| 2026-09-28 | Needham | -- | SELL | -- |
| 2026-09-27 | Citi | -- | SELL | 13.00 |
| 2026-09-15 | J.P. Morgan | -- | HOLD | -- |
| 2026-09-09 | H.C. Wainwright | -- | SELL | 5.00 |
| 2026-09-08 | Wedbush | -- | BUY | 35.00 |
| 2026-09-08 | H.C. Wainwright | -- | SELL | 5.00 |
| 2026-09-01 | J.P. Morgan | -- | HOLD | 23.00 |
| 2026-08-10 | Evercore | -- | HOLD | 19.00 |
| 2026-08-07 | Barclays | -- | HOLD | 20.00 |
| 2026-08-06 | TD Cowen | -- | HOLD | 17.00 |
| 2026-08-06 | Wells Fargo | -- | BUY | 38.00 |
| 2026-08-06 | Piper Sandler | -- | HOLD | 20.00 |
| 2026-08-06 | Wedbush | -- | BUY | 35.00 |
| 2026-08-06 | Morgan Stanley | -- | HOLD | 25.00 |
| 2026-08-06 | Needham | -- | SELL | -- |
| 2026-08-06 | H.C. Wainwright | -- | SELL | 5.00 |
| 2026-08-06 | Oppenheimer | -- | BUY | 35.00 |
| 2026-08-05 | TD Cowen | -- | HOLD | 17.00 |
| 2026-08-05 | Cantor Fitzgerald | -- | HOLD | 21.00 |
| 2026-08-05 | RBC Capital | -- | HOLD | 19.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Hold
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±8.02% | +5.34% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±9.36% | -9.68% (beat) |
| 2025/Q4 | 2026-02-25 | After close | ±9.75% | -8.01% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±19.50% | -33.74% (beat) |
| 2025/Q2 | 2025-08-06 | After close | ±12.42% | +10.46% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±16.88% | -21.45% (beat) |
| 2024/Q4 | 2025-02-26 | After close | ±7.93% | -3.56% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±9.37% | -5.90% (in line) |
| 2024/Q2 | 2024-08-07 | After close | ±10.64% | -2.61% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±7.20% | -0.21% (in line) |
| 2023/Q4 | 2024-02-28 | After close | ±7.92% | -6.98% (in line) |
| 2023/Q3 | 2023-11-01 | After close | ±8.81% | +1.62% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:08:32 · For reference only, not investment advice and not tailored to your situation.